Australian biotech market watch 07/08/09
Friday, 07 August, 2009
All good things... or so they say.
This week saw the mini-correction that some analysts suggest we had to have after a month of uninterrupted rises on the All Ordinaries, with it sitting at 4,290 as of 3.30pm this afternoon, down 0.9% for the day.
The health indices bucked the trend, however, rising a quarter of one percent in today's trading, up 2.5% over the week.
Leading the gains is ResMed (ASX:RMD), up nearly 3% to $5.23 after an announcement that second quarter net income is up 53%, much of the good news being due to currency shifts.
Ramsay Health Care (ASX:RHC) is also up around 2.5% today to $10.82, although much of that is recovering from a dip that started Thursday morning and drove the price down to $10.53.
Biota Holdings (ASX:BTA) has also had a good week, up 2% today to $2.05 - a gain of 6.8% from the week's opening price - mainly due to demand for the anti-viral, Relenza, for which Biota receives royalties.
Sonic Health Care (ASX:SHL) continues to recover from news competition watchdog was considering launching an investigation into pathology billing practices on July 22, returning to its price of $12.24 from that date.
Healthscope (ASX:HSP) took a dive midweek to a low of $4.23, but has recovered to $4.32 in today's trading.
Not much movement from the other two of the Big Three, CSL and Cochlear.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
